Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Matthew J Ridd

doi:10.1016/S0140-6736(23)01523-4

Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Matthew J Ridd

Research output: Contribution to journal › Article (Academic Journal) › peer-review

133 Citations (Scopus)

Original language	English
Journal	The Lancet Regional Health - Europe
DOIs	https://doi.org/10.1016/S0140-6736(23)01523-4
Publication status	Published - 16 Oct 2023

Access to Document

10.1016/S0140-6736(23)01523-4Licence: CC BY

Handle.net

Persistent link

Cite this

@article{944bd5bdd64740b1b9529f24c1602727,

title = "Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.",

author = "Ridd, \{Matthew J\}",

year = "2023",

month = oct,

day = "16",

doi = "10.1016/S0140-6736(23)01523-4",

language = "English",

journal = "The Lancet Regional Health - Europe",

issn = "2666-7762",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

AU - Ridd, Matthew J

PY - 2023/10/16

Y1 - 2023/10/16

U2 - 10.1016/S0140-6736(23)01523-4

DO - 10.1016/S0140-6736(23)01523-4

M3 - Article (Academic Journal)

C2 - 37858323

SN - 2666-7762

JO - The Lancet Regional Health - Europe

JF - The Lancet Regional Health - Europe

ER -